Table 4. Related metabolites that exist at abnormal levels in the urine between MsPGN patients and IgAN patients.
| potential biomarkers | RT | VIP | P | FC |
|---|---|---|---|---|
| Sulfide, allyl methyl | 2.333333 | 1.27078 | 0.025743 | 0.295425 |
| Tartronic acid | 1.158333 | 1.393 | 0.014101 | 0.291611 |
| Benzeneethanamine,N-[(pentafluorophenyl)methylene]-.beta.,4-bis[(trimethylsilyl)oxy]- | 13.05833 | 1.94748 | 0.030319 | 0.28431 |
| Hydrogen azide | 3.05 | 2.32053 | 0.030319 | 0.217254 |
| Carbamic acid | 1.991667 | 1.57673 | 0.011774 | 0.142994 |
Abbreviations: RT, retention time; VIP, variable importance in the projection; FC, fold change, defined as: FC = log10(X2/X1), while X1 denoted the arithmetic mean value of certain metabolite in the MsPGN patients group and X2 denoted the arithmetic mean value in the IgAN patients group. FC with a positive value indicates that the concentration of certain metabolite is relatively higher in IgAN patients compared with MsPGN patients.